Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement

This article was originally published in The Pink Sheet Daily

  • News
  • ­ Steele Thomas

Executive Summary

Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor

You may also be interested in...



Barr Plans To Boost Generic Oral Contraceptive Through Promotion Of Organon's Mircette

A proposed $155 mil. deal would give Barr the NDA for Organon's oral contraceptive and settle ongoing patent litigation related to Barr's Mircette generic.

Barr Plans To Boost Generic Oral Contraceptive Through Promotion Of Organon's Mircette

A proposed $155 mil. deal would give Barr the NDA for Organon's oral contraceptive and settle ongoing patent litigation related to Barr's Mircette generic.

Barr Scraps Seasonale Ad Revisions, Starts On New DTC Campaign

The company attributes a slowdown in growth for the extended-regimen oral contraceptive to the hiatus in direct-to-consumer advertising. The DTC spots were pulled after FDA objected to the original ad and the revised version. New ads will debut in late spring or early summer, CEO Downey says.
Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS061976

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By